Patents Examined by Russell Travers
  • Patent number: 6976981
    Abstract: An osmotic delivery system has a membrane plug retention mechanism which can also be used to control the delivery rate of a beneficial agent from the osmotic delivery system. The osmotic delivery device includes an implant capsule containing a beneficial agent and an osmotic agent. Holes are formed along a side wall of the implant capsule at an open end of the capsule. When the membrane plug is inserted into the open end of the capsule, the membrane material swells into the holes in the capsule side wall creating a large frictional force which prevents expulsion of the membrane plug. A beneficial agent delivery rate of the osmotic delivery system is controllable by varying the size and number of the holes to change the amount of exposed surface area of the membrane plug. An increase in the surface area of the membrane plug exposed to the exterior environment causes a corresponding increase in the liquid permeation rate of the membrane and thus, increases the beneficial agent delivery rate.
    Type: Grant
    Filed: May 17, 2001
    Date of Patent: December 20, 2005
    Assignee: Alza Corporation
    Inventor: Rupal Ayer
  • Patent number: 6962927
    Abstract: The specification discloses a method for enhancing the inhibiting action of drugs against multidrug resistant cells, apparently by reversing or inhibiting the glycoprotein “pumps” associated with such cells.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 8, 2005
    Assignee: Cancer Biologics of America, Inc.
    Inventor: Knox Van Dyke
  • Patent number: 6911454
    Abstract: The specification discloses a method for enhancing the inhibiting action of drugs against multidrug resistant cells, apparently by reversing or inhibiting the glycoprotein “pumps” associated with such cells.
    Type: Grant
    Filed: August 22, 1994
    Date of Patent: June 28, 2005
    Assignee: Cancer Biologics of America, Inc.
    Inventor: Knox Van Dyke
  • Patent number: 6896897
    Abstract: A flexible applicator for applying an oil-in-water emulsion comprises: (1) an allantoin-containing oil-in-water emulsion; and (2) a flexible element that adsorbs or absorbs the emulsion such that the emulsion is applied to the skin of a patient on whom the flexible applicator is placed. The allantoin-containing emulsion, containing allantoin and an emulsifier, has improved stability coming from the adjustment of the pH to a range of 3.0 to 6.0; preferably, the pH is in the range of 4.5 to about 5.8. The lower pH preserves the stability of the allantoin and the functionality of the emulsifier system is maintained. The emulsifier system can be a nonionic emulsifier or an anionic emulsifier plus beeswax. The acid used to adjust the pH can be an organic acid or an inorganic acid. The emulsion can further comprise other ingredients such as herbal extracts, chelating agents, preservatives, emollients, solvents, and fragrance.
    Type: Grant
    Filed: August 27, 2001
    Date of Patent: May 24, 2005
    Assignee: Alwyn Company, Inc.
    Inventor: Elliott Farber
  • Patent number: 6894056
    Abstract: A method for alleviating chronic fatigue syndrome with the administration of antiviral agents. Based on clinical tests, chronic fatigue syndrome is a persistent herpes virus infection including incomplete virus multiplication and thus administration of antiviral agents are shown to alleviate the symptoms associated with the disorder. Based on therapeutic trials, patients receiving the recommended antiviral treatment, have experienced significant reduction or elimination of the symptoms associated with chronic fatigue syndrome. A method of diagnosis of the chronic fatigue syndrome is further disclosed.
    Type: Grant
    Filed: January 30, 2002
    Date of Patent: May 17, 2005
    Inventor: A. Martin Lerner
  • Patent number: 6894068
    Abstract: The present invention provides compositions and methods for the treatment of HIV infection. In particular, the present invention provides non-nucleoside inhibitors of reverse transcriptase (RT), as well as methods to treat HIV infection using these non-nucleoside inhibitors of RT. In preferred embodiments, the present invention provides a novel class of substituted benzimidazoles, effective in the inhibition of human immunodeficiency virus (HIV) RT.
    Type: Grant
    Filed: April 9, 2002
    Date of Patent: May 17, 2005
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Christopher J. Michejda, Marshall Morningstar, Thomas Roth
  • Patent number: 6887879
    Abstract: In accordance with the present invention there is provided a pharmaceutical combination useful for the treatment of viral infections comprising a at least one antiviral active compound of formula (1): and at least one further therapeutic agent chosen from nucleoside analogues; NNRTIs; and protease inhibitors.
    Type: Grant
    Filed: May 16, 2002
    Date of Patent: May 3, 2005
    Assignee: Shire BioChem Inc.
    Inventors: Robert F. Rando, Zhengxian Gu
  • Patent number: 6881748
    Abstract: A bioreductive conjugate comprises a bioreductive moiety with at least one therapeutic agent linked thereto and physiologically acceptable derivatives thereof. The bioreductive moiety incorporates an aromatic ring substituted with a nitro group and the conjugate is such that bioreduction of the nitro group causes release of the therapeutic agent by a through bond elimination and the residue of the bioreductive moiety to undergo an intramolecular cyclization reaction in which the nitrogen of the original nitro group provides an atom of the thus formed ring.
    Type: Grant
    Filed: August 19, 1999
    Date of Patent: April 19, 2005
    Assignee: The Victoria University of Manchester
    Inventors: Sally Freeman, Mohammed Jaffor, Ian Stratford
  • Patent number: 6867178
    Abstract: An enteral composition and method for providing nutrition to metabolically stressed patients. The enteral composition has an energy density of about 1.4 to 1.8 kcal/ml. The enteral composition includes a protein source providing 15% to 20% of the energy of the composition, a lipid source, and a carbohydrate source. The enteral composition has a ratio of non-protein calories per gram of nitrogen of at least about 90:1.
    Type: Grant
    Filed: December 30, 1998
    Date of Patent: March 15, 2005
    Assignee: Nestec S.A.
    Inventors: David A. Mark, Diana Twyman, Tom Michalski
  • Patent number: 6864274
    Abstract: An allantoin-containing skin cream composition can comprise allantoin and at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water. The pH of the composition is in a range of from about 3.0 to about 6.0; preferably, the pH of the composition is from about 5.0 to about 6.0. The composition can further comprise an acidic anionic polymer. A preferred acidic anionic polymer is a carboxypolymethylene polymer. The composition can further comprise a carbohydrate polymer such as galactoarabinan, polygalactose or polyarabinose. The composition can additionally comprise other ingredients such as herbal extracts, an antioxidant component, an emollient component, a chelator, a solvent component, or a preservative component. The composition is useful as a skin protectant.
    Type: Grant
    Filed: January 11, 2001
    Date of Patent: March 8, 2005
    Assignee: Alwyn Company, Inc.
    Inventor: Elliott Farber
  • Patent number: 6861441
    Abstract: The present invention relates to the use of an EP4 receptor ligand in the manufacture of a medicament for use in the treatment of neuropathic pain, colon cancer, migraine, and for increasing the latency of HIV infection.
    Type: Grant
    Filed: August 8, 2000
    Date of Patent: March 1, 2005
    Assignee: SmithKline Beecham Corporation
    Inventors: Nicholas Maughan Clayton, Susanne Denise Collins, Steven Michael Foord, Gerard Martin Paul Giblin, Richard John Coles, Mark Bamford, Jennifer M Doughty, Richard Green
  • Patent number: 6849595
    Abstract: The present invention provides an enteral composition and method for providing nutrition to metabolically stressed patients. Pursuant to the present invention, the enteral composition has an increased caloric density of approximately 1.4 to 1.8 kcal/mL. The enteral composition includes a peptide based protein source, a lipid source, and a carbohydrate source.
    Type: Grant
    Filed: January 10, 2001
    Date of Patent: February 1, 2005
    Assignee: Nestec S.A.
    Inventors: David A. Mark, Diana Twyman, Tom Michalski
  • Patent number: 6844359
    Abstract: Novel imides are inhibitors of tumor necrosis factor alpha and can be used to combat cachexia, endotoxic shock, and retrovirus replication. A typical embodiment is (R)-2-Phthalimido-3-(3?,4?-dimethoxyphenyl)propane.
    Type: Grant
    Filed: March 25, 2002
    Date of Patent: January 18, 2005
    Assignee: Celgene Corporation
    Inventors: George W. Muller, Mary Shire, David I. Stirling
  • Patent number: 6838477
    Abstract: Described herein are compounds related to lactacystin and lactacystin ?-lactone, pharmaceutical compositions containing the compounds, and methods of use.
    Type: Grant
    Filed: August 8, 2001
    Date of Patent: January 4, 2005
    Assignee: President and Fellows of Harvard College
    Inventors: Stuart L. Schreiber, Robert F. Standaert, Gabriel Fenteany, Timothy F. Jamison
  • Patent number: 6825177
    Abstract: Methods for increasing the elimination half-life of key metabolites such as d4T by administering an aryl phosphate derivative of d4T having an electron withdrawing substituent on the aryl group and an amino acid substituent on the phosphate group are described. A preferred aryl phosphate derivative of d4T is HI-113 (d4T-5′-[p-bromophenyl methoxyalaninyl phosphate]). The administration of HI-113 results in more prolonged systemic exposure to the key metabolites, Ala-d4T-MP and d4T, than administration of an equimolar dose of either metabolite. Each metabolite has a significantly longer elimination half life when formed in vivo from the administration of HI-113 than when the metabolite is administered directly.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: November 30, 2004
    Assignee: Parker Hughes Institute
    Inventors: Fatih Uckun, Chun-Lin Chen, Taracad K. Venkatachalam, Zhoa-Hai Zhu
  • Patent number: 6815461
    Abstract: Disclosed is a method of inhibiting retroviral integrase in a subject in need of such treatment. The method comprises administering to the subject an effective retroviral integrase inhibiting amount of a bis-benzimidazole compound such as bis[5-amidino-2-benzimidazolyl]methane, 1,2-bis[5-amidino-2-benzimidazolyl]ethane, 1,2-bis[5-amidino-2-benzimidazolyl]ethene or a pharmaceutically acceptable salt thereof. A method for combatting retroviral infections is also disclosed.
    Type: Grant
    Filed: January 20, 1994
    Date of Patent: November 9, 2004
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Christine C. Dykstra, Ronald I. Swanstrom, Richard R. Tidwell
  • Patent number: 6803375
    Abstract: Compounds, preparations and methods for immunosuppressive treatment of autoimmune disorders, graft rejection and/or graft/host disease. Therapeutically effective amounts of certain substituted triarylmethane compounds, such as 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole, are administered to mammalian patients to selectively inhibit the calcium-activated K+ channel (IKCa1) in lymphocytes, monocytes, macrophages, platelets or endothelial cells without concomitant inhibition of P450-dependent enzyme systems, resulting in reduction of antigen-, cytokine-, or mitogen-induced calcium entry through store operated calcium channels in these cells, suppression of cytokine production by these cells, and inhibition of activation of these cells. Such inhibition of the Ca++ activated K+ channel (IKCa1) prevents the pre-Ca++ stage of cell activation and thus causes immunosuppression and an anti-inflammatory response.
    Type: Grant
    Filed: January 6, 2000
    Date of Patent: October 12, 2004
    Assignee: The Regents of the University of California
    Inventors: K. George Chandy, Heike Wulff
  • Patent number: 6797729
    Abstract: Compositions comprising glutamine in combination with other ingredients such as N-acetyl-cysteine are disclosed. Such compositions can be administered to treat patients with certain conditions of the body.
    Type: Grant
    Filed: June 27, 1997
    Date of Patent: September 28, 2004
    Assignee: Baxter International Inc.
    Inventors: Theresa A. Byrne, Joanne A. Somerville
  • Patent number: 6797255
    Abstract: Substantially nontoxic manganese complexes of compounds of the formula: wherein n=0, 1 or 2, R1 and R2 are hydrogen or alkyl groups of 1 to 4 carbon atoms, and R3 and R4 are hydrogen, alkyl groups of 1 to 4 carbon atoms or halogen, are useful for enhancing magnetic resonance images of body organs and tissues. Illustrative manganese complexes of such compounds include dihydrogen bis(N-[N′-(2,6-Diisopropylphenyl)-carbamoylmethyl-]iminodiaceto)manganese(II) monohydrate, dihydrogen bis[N-[N′-(2,6-dimethylphenyl)-carbamoylmethyl]iminodiaceto)-manganese(II) trihydrate, and dihydrogen bis(N-[N′-(2,6-dimethylpheny)carbamoylmethyl]iminodiaceto) manganese(II) dihydrate.
    Type: Grant
    Filed: October 17, 1991
    Date of Patent: September 28, 2004
    Assignee: Mallinckrodt Inc.
    Inventors: Richard T. Dean, George Brooke Hoey
  • Patent number: 6790451
    Abstract: A cosmetic material comprising as essential cosmetic constituents (A) a silicone-branched silicone compound and (B) a silicone-branched polyether-modified silicone compound.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: September 14, 2004
    Assignee: Shin-Etsu Chemical Co., Ltd.
    Inventor: Tetsuo Nakanishi